- Home
- SGN vs NCNA Comparison
SGN vs NCNA Comparison
Compare SGN & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- NCNA
- Stock Information
- Founded
- SGN 2019
- NCNA 1997
- Country
- SGN United States
- NCNA United Kingdom
- Employees
- SGN N/A
- NCNA N/A
- Industry
- SGN
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- NCNA Health Care
- Exchange
- SGN Nasdaq
- NCNA Nasdaq
- Market Cap
- SGN 4.1M
- NCNA 4.4M
- IPO Year
- SGN 2023
- NCNA 2017
- Fundamental
- Price
- SGN $0.18
- NCNA $1.49
- Analyst Decision
- SGN
- NCNA Buy
- Analyst Count
- SGN 0
- NCNA 2
- Target Price
- SGN N/A
- NCNA $25.00
- AVG Volume (30 Days)
- SGN 4.9M
- NCNA 138.4K
- Earning Date
- SGN 11-25-2024
- NCNA 11-26-2024
- Dividend Yield
- SGN N/A
- NCNA N/A
- EPS Growth
- SGN N/A
- NCNA N/A
- EPS
- SGN N/A
- NCNA N/A
- Revenue
- SGN $576,488.00
- NCNA N/A
- Revenue This Year
- SGN N/A
- NCNA N/A
- Revenue Next Year
- SGN N/A
- NCNA N/A
- P/E Ratio
- SGN N/A
- NCNA N/A
- Revenue Growth
- SGN 218.74
- NCNA N/A
- 52 Week Low
- SGN $0.11
- NCNA $1.49
- 52 Week High
- SGN $2.70
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- SGN 42.04
- NCNA 34.09
- Support Level
- SGN $0.18
- NCNA $1.53
- Resistance Level
- SGN $0.29
- NCNA $1.66
- Average True Range (ATR)
- SGN 0.03
- NCNA 0.09
- MACD
- SGN -0.00
- NCNA 0.05
- Stochastic Oscillator
- SGN 18.66
- NCNA -3.70
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.